{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T21:30:39Z","timestamp":1786915839807,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004681","name":"Higher Education Commission, Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nucmedbio.2026.109606","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:10:03Z","timestamp":1769616603000},"page":"109606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Mesothelin-targeted alpha therapy in PDAC with [225Ac]Ac-Macropa-PEG6-Amatuximab"],"prefix":"10.1016","volume":"154-155","author":[{"given":"Syed Qaiser","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Santos-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeeha","family":"Shabnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"DeryaIlem-Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109606_bb0005","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/diagnostics11030562","article-title":"Pancreatic ductal adenocarcinoma: epidemiology and risk factors","volume":"11","author":"Ushio","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0010","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.3390\/cancers14163946","article-title":"Clinical outcome and prognostic factors of pancreatic adenosquamous carcinoma compared to ductal adenocarcinoma\u2014results from the German Cancer Registry Group","volume":"14","author":"Braun","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0015","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10238-022-00886-1","article-title":"Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies","volume":"23","author":"Kuznetsova","year":"2022","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0020","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/cancers13143481","article-title":"Dynamic stromal alterations influence tumor-stroma crosstalk to promote pancreatic cancer and treatment resistance","volume":"13","author":"Murphy","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11523-018-0567-0","article-title":"The Role of mesothelin as a diagnostic and therapeutic target in pancreatic ductal adenocarcinoma: a comprehensive review","volume":"13","author":"Nichetti","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0035","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0050","first-page":"7","article-title":"Mesothelin as a biomarker for targeted therapy","author":"Lv","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1358\/dof.2013.38.12.2086908","article-title":"Amatuximab","volume":"38","author":"Antoniu","year":"2013","journal-title":"Drugs Future"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0060","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.2147\/OTT.S145105","article-title":"Amatuximab and novel agents targeting mesothelin for solid tumors","volume":"10","author":"Baldo","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0065","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s10637-021-01118-1","article-title":"Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model","volume":"39","author":"Fujii","year":"2021","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1874471011104040306","article-title":"Actinium-225 in targeted alpha-particle therapeutic applications","volume":"4","author":"A. Scheinberg","year":"2011","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/jmp.jmp_22_24","article-title":"Actinium-225 in targeted alpha therapy","volume":"49","author":"Rahman","year":"2024","journal-title":"J Med Phys"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0080","first-page":"8","article-title":"Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis","author":"Sgouros","year":"2021","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1874471011666180416161908","article-title":"Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences","volume":"11","author":"Robertson","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/ph17010076","article-title":"Alpha-emitting radionuclides: current status and future perspectives","volume":"17","author":"Miederer","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1039\/C3JA50277E","article-title":"DOTA based metal labels for protein quantification: a review","volume":"29","author":"Schwarz","year":"2014","journal-title":"J Anal At Spectrom"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0100","first-page":"10","article-title":"Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE","author":"Hooijman","year":"2025","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0105","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1021\/acs.bioconjchem.2c00190","article-title":"H2BZmacropa-NCS: a bifunctional chelator for actinium-225 targeted alpha therapy","volume":"33","author":"Kadassery","year":"2022","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0110","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/acs.accounts.2c00003","article-title":"Advancing chelation strategies for large metal ions for nuclear medicine applications","volume":"55","author":"Hu","year":"2022","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0115","doi-asserted-by":"crossref","first-page":"14904","DOI":"10.1002\/ange.201709532","article-title":"An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy","volume":"129","author":"Thiele","year":"2017","journal-title":"Angew Chem"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0120","first-page":"235","article-title":"Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors","volume":"15","author":"Kennel","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0125","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1158\/1078-0432.CCR-07-4647","article-title":"Preclinical evaluation of the \u03b1-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors","volume":"14","author":"Miederer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0140","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-23-3746","article-title":"Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab): a targeted alpha therapy for prostate cancer","volume":"30","author":"Schatz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/1078-0432.CCR-24-1779","article-title":"Complete remissions of HER2-positive trastuzumab-resistant xenografts using a potent [225Ac]Ac-labeled anti-HER2 antibody\u2013drug radioconjugate","volume":"31","author":"Pougoue Ketchemen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0150","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1021\/acs.molpharmaceut.0c00703","article-title":"Evaluating 225Ac and 177Lu radioimmunoconjugates against antibody\u2013drug conjugates for small-cell lung cancer","volume":"17","author":"Lakes","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0155","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/bc990153f","article-title":"Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for225Ac radioimmunotherapy applications","volume":"11","author":"Chappell","year":"2000","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0160","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/molecules28030917","article-title":"Site-specific antibody conjugation with payloads beyond cytotoxins","volume":"28","author":"Zhou","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/abt\/tbaa027","article-title":"Site-specific conjugation of native antibody","volume":"3","author":"Sadiki","year":"2020","journal-title":"Antibody Ther"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0170","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/mp500781a","article-title":"Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody\u2013drug conjugate SYD985","volume":"12","author":"Elgersma","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0175","first-page":"336","article-title":"Actinium-225 for targeted \u03b1 therapy: coordination chemistry and current chelation approaches","volume":"33","author":"Thiele","year":"2018","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","article-title":"Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0185","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1039\/D3SC06365H","article-title":"Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX","volume":"15","author":"Morgan","year":"2024","journal-title":"Chem Sci"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0190","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2026.109606_bb0195","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/ijms21114067","article-title":"From malignant progression to therapeutic targeting: current insights of mesothelin in pancreatic ductal adenocarcinoma","volume":"21","author":"Montemagno","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:58:07Z","timestamp":1778792287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"alternative-id":["S0969805126000053"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109606","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelin-targeted alpha therapy in PDAC with [225Ac]Ac-Macropa-PEG6-Amatuximab","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109606"}}